Company intelligence / Profile preview

Black Canyon Bio

Phoenix, Arizona, United Statesblackcanyonbio.com ↗

Ownership: Private
Development stage: Other

Overview

Black Canyon Bio is developing personalized cancer therapies using its proprietary SNAP Technology platform. Its lead programs include a personalized cancer vaccine and a TIL-based cell therapy. The first clinical trials began in 2024, with at least one program reaching Phase 1 for breast cancer. No published clinical results are available as of June 2025.

Therapeutic areas: DermatologyGastroenterologyOncology
Modalities: Synthetic peptide vaccinemRNA vaccineCell therapyTIL therapy (Tumor Infiltrating Lymphocyte therapy)Therapeutic vaccine
Industry: Biotech

Drug pipeline

1 asset

SNAPduo 101

Preclinical

Partnerships

Translational Genomics Research Institute (TGen), part of City of Hope Medical Network (technology originator/collaborator)

Beyond the preview

Go deeper on Black Canyon Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Black Canyon Bio.

Explore the full profile